Triplixam Contraindications

Dialysis patients.
Patients with untreated decompensated heart failure.
Severe renal impairment (creatinine clearance below 30 mL/min).
Moderate renal impairment (creatinine clearance below 60 mL/min) for Perindopril arginine + Indapamide + Amlodipine (TRIPLIXAM) doses containing 10 mg/2.5mg of perindopril/indapamide combination (i.e., Perindopril arginine + Indapamide + Amlodipine (TRIPLIXAM) 10 mg/2.5 mg/10 mg).
Hypersensitivity to the active substances, to other sulfonamides, to dihydropyridine derivatives, any other ACE-inhibitor or to any of the excipients.
History of angioedema (Quincke's edema) associated with previous ACE inhibitor therapy.
Hereditary/idiopathic angioedema.
Second and third trimesters of pregnancy.
Hepatic encephalopathy.
Severe hepatic impairment.
Hypokalemia.
Severe hypotension.
Shock, including cardiogenic shock.
Obstruction of the outflow-tract of the left ventricle (e.g. high grade aortic stenosis).
Hemodynamically unstable heart failure after acute myocardial infarction.
Concomitant use of Perindopril arginine + Indapamide + Amlodipine (TRIPLIXAM) with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60mL/min/1.73m²).
Concomitant use with sacubitril/valsartan. Triplixam must not be initiated earlier than 36 hours after the last dose of sacubitril/valsartan.
Extracorporeal treatments leading to contact of blood with negatively charged surfaces.
Significant bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney.